This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
by Zacks Equity Research
GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.
Here's How Charles River is Placed Just Ahead of Q1 Earnings
by Zacks Equity Research
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
by Zacks Equity Research
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Beat the Market the Zacks Way: ProAssurance, Stride, Hershey in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
by Zacks Equity Research
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
by Zacks Equity Research
UHS' first-quarter earnings are likely to have benefited from growing admissions and patient days.
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
by Zacks Equity Research
HCA's first-quarter earnings are likely to have benefited from growing admissions.
Can Centene Beat Q1 Earnings Estimates on Growing Premiums?
by Zacks Equity Research
CNC's first-quarter results are likely to benefit from higher commercial marketplace memberships.
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
by Zacks Equity Research
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch
by Zacks Equity Research
MOH's first-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Should First Trust Growth Strength ETF (FTGS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTGS
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
by Harshit Gupta
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BAX Stock Declines Despite Latest Product Launch Boosting Patient Care
by Zacks Equity Research
Baxter aims to promote enhanced patient care through the evolution of its latest product, which enables direct accessibility in the operating room.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Beat the Market the Zacks Way: Casey's, Stride, McDonald's in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence
by Sridatri Sarkar
In the present market turbulence, investors may want to consider discounted stocks, such as FMS, PAHC and COR.
ICUI Stock Gains Following Latest FDA Approvals for Precision IV Pumps
by Zacks Equity Research
ICU Medical aims to enable healthcare systems to customize infusion setups, optimizing device footprint without compromising performance or safety.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
by Zacks Equity Research
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
by Ritujay Ghosh
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.